Department of Head and Neck Surgery, University Hospital Ghent, Belgium.
Cancer Biother Radiopharm. 2011 Jun;26(3):331-4. doi: 10.1089/cbr.2010.0918. Epub 2011 Jun 28.
The purpose of this study was to assess the potential of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging for detection of the primary tumor and its impact on treatment planning in patients presenting with cancer of unknown primary and squamous cell carcinoma (SCC)-positive cervical lymph nodes of the upper and middle neck.
The study population consisted of 18 consecutive patients with biopsy-proven SCC involving lymph nodes of the upper and middle neck region and negative conventional diagnostic procedures with regard to the location of the primary. All patients underwent FDG-PET/CT according to a standard procedure in search for the primary, unidentified tumor.
In none of the patients FDG-PET/CT was able to indicate a primary tumor localization. Although FDG-PET/CT did identify all sites of known lymph node involvement, neither additional sites of lymph node involvement nor sites of distant metastases were identified. Accordingly, FDG-PET/CT did not impact patient treatment planning.
In this series, including patients suffering from lymph node metastases by an SCC of unknown primary in the upper and middle neck, FDG-PET/CT was unable to identify a primary tumor. In addition, FDG-PET/CT did not modify the treatment planning in any of the patients studied.
本研究旨在评估氟-18-脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）成像在检测原发肿瘤及其对中颈上部鳞状细胞癌（SCC）阳性颈淋巴结转移的患者治疗计划的影响的潜力。
该研究人群包括 18 例经活检证实的 SCC 患者，这些患者的颈上部和中部区域淋巴结受累，且常规诊断程序未能确定原发灶的位置。所有患者均按标准程序进行 FDG-PET/CT 检查，以寻找原发灶和未确定的肿瘤。
在没有一例患者中，FDG-PET/CT 能够确定原发肿瘤的定位。尽管 FDG-PET/CT 确实确定了所有已知淋巴结受累的部位，但未发现额外的淋巴结受累部位或远处转移部位。因此，FDG-PET/CT 并未影响患者的治疗计划。
在本系列中，包括患有上颈和中颈 SCC 未知原发灶的淋巴结转移的患者，FDG-PET/CT 未能确定原发肿瘤。此外，FDG-PET/CT 未改变研究中任何患者的治疗计划。
